Related references
Note: Only part of the references are listed.Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi et al.
BLOOD (2010)
Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients
E. Pautas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort
J. A. Perini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
L. H. Cavallari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
COUNTERPOINT - Pharmacogenetic-Based Initial Dosing of Warfarin: Not Ready for Prime Time
Charles S. Eby
CLINICAL CHEMISTRY (2009)
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Jonatan D. Lindh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Myong-Jin Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
Matthew G. McDonald et al.
MOLECULAR PHARMACOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
P. Borgiani et al.
PHARMACOGENOMICS (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
Oral anticoagulants: Pharmacogenetics relationship between genetic and non-genetic factors
Giovanna D'Andrea et al.
BLOOD REVIEWS (2008)
Pharmacogenomics of 4-hydroxycoumarin anticoagulants
Nicholas Au et al.
DRUG METABOLISM REVIEWS (2008)
A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding
Monica R. McClain et al.
GENETICS IN MEDICINE (2008)
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1
D. J. Harrington et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
Nita A. Limdi et al.
PHARMACOGENOMICS (2008)
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
Hedi Schelleman et al.
PHARMACOGENOMICS (2008)
Warfarin pharmacogenetics
Nita A. Limdi et al.
PHARMACOTHERAPY (2008)
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Natasa Djordjevic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Jeffrey L. Anderson et al.
CIRCULATION (2007)
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians
Paold Borgiani et al.
PHARMACOGENOMICS (2007)
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives
Tong Yin et al.
THROMBOSIS RESEARCH (2007)
Association of warfarin dose with genes involved in its action and metabolism
Mia Wadelius et al.
HUMAN GENETICS (2007)
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Harumi Takahashi et al.
PHARMACOGENETICS AND GENOMICS (2006)
Worldwide management of oral anticoagulant therapy: the ISAM study
V Pengo et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2006)
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
JD Lindh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Updated definitions of healthy ranges for serum alanine aminotransferase levels
D Prati et al.
ANNALS OF INTERNAL MEDICINE (2002)
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Pharmacogenetics of warfarin elimination and its clinical implications
H Takahashi et al.
CLINICAL PHARMACOKINETICS (2001)
Clinically significant pharmacokinetic interactions between dietary caffeine and medications
JA Carrillo et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
